Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit ...

Gulf South Angels, a New Orleans-based investment network, is investing in non-opioid pain drug startup South Rampart Pharma, ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend.

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...

One point of concern shared by local recovery advocates is the possible loss of state and federal grants that pay for Narcan ...

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 0.95%) on Casgevy. Although Vertex takes a ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded rating to 'Buy.' Discover why!

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX stock a Buy.